MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1–resistant tumors
Near-term capital transactions poised to bolster liquidity
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the first quarter of 2025 and provided a business update highlighting continued clinical progress and strategic developments across its iNKT platform. The company will host a conference call and webcast today at 8:30 a.m. ET.
'This quarter marks a turning point in the evolution of MiNK. Our platform is demonstrating the power of iNKT cells to transform immune responses in both cancer and inflammatory diseases,' said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. 'With late-stage strategic discussions underway across oncology, immunology, and next-generation engineered cell therapies, MiNK is positioned to unlock the full value of our technology. These partnerships—alongside our clinical advances and expanded access to non-dilutive capital—will allow us to deliver off-the-shelf iNKT therapies to patients with urgency, focus, and scale.'
Key Highlights from Q1 2025
Strategic and Business Development
Advanced discussions on distinct transactions aligned with core areas of MiNK's platform--oncology, immune-mediated diseases, and next-generation engineered cell therapies--designed to broaden MiNK's reach while preserving optionality and shareholder value.
Clinical Progress in Cancer, Immunity, and Inflammation
MiNK continues to expand the clinical and strategic value of its iNKT platform across solid tumors and immune-mediated diseases.
At AACR IO and ASCO GI, MiNK presented new data showing that agenT-797, in combination with checkpoint inhibitors and chemotherapy, drives rapid tumor infiltration, CD8+ T cell activation, and immune reprogramming in PD-1–resistant gastroesophageal cancers—a population with limited therapeutic options.
A Phase 2 trial (NCT06251973), led by Memorial Sloan Kettering Cancer Center, is actively enrolling in second-line gastric cancer.
A peer-reviewed publication expected in the first half of 2025 will detail a complete remission in a patient with metastatic testicular cancer treated in MiNK's Phase 1 trial with a single infusion of agenT-797—achieved without lymphodepletion, HLA matching, or toxicity. This case reinforces the differentiated potential of MiNK's off-the-shelf iNKT platform in solid tumors that are refractory to standard treatments and immunotherapy.
In ARDS, MiNK's iNKT therapy continues to demonstrate survival benefit and inflammatory control, as published in Nature Communications and presented at the American Thoracic Society. The company is pursuing broader patient access through clinical trials and compassionate use programs.
In parallel, MiNK has been selected for probable funding by NIAID to support its allogeneic iNKT program in GvHD, with a formal award expected by June 2025. This recognition adds a critical source of non-dilutive capital and external validation of MiNK's leadership in inflammation and immune modulation.
Together, these programs represent high-value expansion opportunities across MiNK's core verticals: solid tumors, inflammatory disease, and next-generation engineered cell therapies.
Financial Highlights
MiNK ended the quarter with a cash balance of $3.2 million. Cash used in operations for the three months ended March 31, 2025 was $1.3 million compared to $2.5 million for the same period in 2024. Net loss for the first quarter of 2025 was $2.8 million, or $0.70 per share, compared to $3.8 million, or $1.10 per share, for the first quarter of 2024.
Summary Consolidated Financial Information
Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)
March 31, 2025
December 31, 2024
Cash and cash equivalents
$
3,235
$
4,577
Total assets
4,267
5,721
Other Financial Information
(in thousands)
(unaudited)
Three months ended March 31,
2025
2024
Cash used in operations
$
1,341
$
2,542
Non-cash expenses
835
650
Condensed Consolidated Statements of Operations Data
(in thousands, except per share data)
(unaudited)
Three months ended March 31,
2025
2024
Operating expenses:
Research and development
$
1,262
$
2,550
General and administrative
1,271
1,280
Change in fair value of related party note
168
Operating loss
2,701
3,830
Other income, net
66
(17
)
Net loss
$
2,767
$
3,813
Per common share data, basic and diluted:
Net loss
$
(0.70
)
$
(1.10
)
Weighted average number of common shares outstanding, basic and diluted
3,965
3,464
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 9822477
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company's website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/jgzwe9ny/.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
About AgenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as 'master regulators,' combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors.
Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, Oncogene. 2024) and to combat inflammation in critically ill patients with severe respiratory pathology (Nature Communications. 2024).
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells, as well as the collaboration between MiNK and Agenus. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Agenus with no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Why Casey's General Stores Stock Skyrocketed This Week
Casey's General Stores is quietly the fifth-largest pizza chain in the United States. It continues to grow its geographic footprint beyond the Midwest, and is now in 20 states. Leaning on its ability to make shrewd acquisitions, Casey's growth story could still be in its early chapters. 10 stocks we like better than Casey's General Stores › Shares of Midwestern pizza and convenience store chain Casey's General Stores (NASDAQ: CASY) were 13% higher this week as of 12:30 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence. Reporting fourth-quarter earnings, Casey's delivered earnings before interest, taxes, depreciation, and amortization (EBITDA) and earnings per share growth of 20% and 12%, surpassing analysts' expectations. This booming profitability, paired with management's announcement of a 14% dividend increase, sent Casey's shares skyward. Casey's General Stores operates approximately 2,900 locations, primarily located in small towns across the Midwest. As it expanded beyond its roots in Iowa to its current footprint of 20 states, the company has become a 258-bagger since 1990. Despite this incredible run, I recently wrote that Casey's is still an excellent long-term buy -- despite nearing all-time highs. And again, I'd argue it still looks pretty promising even after this week's run-up. Growing its store count by 9% in 2025, management's expansion plans show no signs of slowing. Powered by its mergers and acquisitions team, Casey's has been expanding into new states, like Texas, Tennessee, and Florida. The reason this M&A model works so well is that Casey's typically focuses on buying convenience stores without a strong food presence. Then it adds a Casey's kitchen, bringing in its beloved pizza-making and prepared food capabilities to these new locations, boosting profitability and generating a strong return on its investment. However, even with its recent success, the company's valuation remains reasonable at 17 times cash from operations (CFO). For example, whereas Casey's has grown its net income by 19% annually over the last decade, Domino's Pizza has only grown its profits by 14% over the same time, yet trades at 23 times CFO. Before you buy stock in Casey's General Stores, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Casey's General Stores wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor's total average return is 998% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Josh Kohn-Lindquist has positions in Casey's General Stores. The Motley Fool has positions in and recommends Domino's Pizza. The Motley Fool recommends Casey's General Stores. The Motley Fool has a disclosure policy. Why Casey's General Stores Stock Skyrocketed This Week was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
KBW Announces Index Rebalancing for Second-Quarter 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), announces the upcoming index rebalancing for the second quarter of 2025. This quarter, there are constituent changes within one of our indexes: KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX, ETF Ticker: KBWY). These changes will be effective prior to the opening of business on Monday, June 23, 2025. As part of this rebalancing, below are the component-level changes across impacted indices: KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX; ETF Ticker: KBWY) Drop (1): SITE Centers Corp. (NYSE: SITC) Several of the KBW Nasdaq indexes have tradable exchange‐traded funds licensed: KBW Nasdaq Bank Index (Index Ticker: BKXSM, ETF Ticker: KBWBSM); KBW Nasdaq Capital Markets Index (Index Ticker: KSXSM); KBW Nasdaq Insurance Index (Index Ticker: KIXSM); KBW Nasdaq Regional Banking Index (Index Ticker: KRXSM, ETF Ticker: KBWRSM); KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDXSM, ETF Ticker: KBWDSM); KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYXSM, ETF Ticker: KBWYSM); KBW Nasdaq Property and Casualty Insurance Index (Index Ticker: KPXSM, ETF Ticker: KBWPSM); KBW Nasdaq Global Bank Index (Index Ticker: GBKXSM); KBW Nasdaq Financial Technology Index (Index Ticker: KFTXSM, ETF Ticker: Not all of the listed securities may be suitable for retail investors; in addition, not all of the listed securities may be available to U.S. investors. European investors interested in FTEK LN can contact Invesco at U.S. investors cannot buy or hold FTEK LN. An investor cannot invest directly in an index. About KBW KBW (Keefe, Bruyette & Woods, Inc., operating in the U.S., and Stifel Nicolaus Europe Limited, also trading as Keefe, Bruyette & Woods Europe, operating in Europe) is a Stifel company. Over the years, KBW has established itself as a leading independent authority in the banking, insurance, brokerage, asset management, mortgage banking and specialty finance sectors. Founded in 1962, the firm maintains industry‐leading positions in the areas of research, corporate finance, mergers and acquisitions as well as sales and trading in equities securities of financial services companies. Media Contact Neil Shapiro, (212) 271-3447shapiron@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Michiganders are returning fewer bottles and cans. Why?
GRAND RAPIDS, Mich. (WOOD) — The value of a dime doesn't stretch as far as it did in 1976 when the state's bottle deposit law was initiated, but for many Michiganders, returning beverage containers to get their 10 cents back sure adds up. 'I don't want to throw my pennies and dimes away,' Grand Rapids resident Mildred Griffin said. 'The cost of living is so high right now. You would be a fool to throw away 10 cents.' For Griffin, returning bottles and cans is a way of life. She said it's like getting paid to recycle. She was surprised to learn that fewer people are turning in their bottles to get that dime back. Statewide return rates have fallen to their lowest point. In 2024, just over 70% of bottles and cans were returned. Workers at a number of local markets told News 8 they have seen fewer returns in recent years. At Kingma's Market in Grand Rapids, owner Alan Hartline said the redemption process adds complications to store owners. He said the process, from collecting to sorting, is in serious need of an update. 'It really taxes the supply chain and adds a lot of cost to it for businesses,' he said, 'I think there can be a better way to facilitate it. It should be earth friendly, but perhaps to do it without the cost and as many hoops as the current process today.' Sen. Sean McCann, D-Kalamazoo, also believes there's a need for change, including an expansion. 'Even though we've come off our highs, habits have changed, there's a real ability to still improve our system and make it get better,' he said. McCann reintroduced a bill to modify the bottle return law to include other containers, primarily plastic water bottles. 'I think it's terrible that we have over 2 billion plastic water bottles that don't necessarily get recycled and often get landfilled and are not eligible for the deposit,' he said. He's also pushing for bottles and cans to be returnable anywhere — not just at chains that carry the brands being returned. He said that is part of the reason the rates are dropping. 'Part of the bugaboo is a universal redemption,' he said. 'You buy something at one store (but) you can't take it back to the other store.' For McCann, the goal is to get the issue on the ballot and let the citizens decide. 'This is not something worth giving up on for me,' he said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
